This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
NECTIN3 / Nectin-3 · IHC design guide
Design Immunohistochemistry for NECTIN3
Plan NECTIN3 staining in paraffin sections using its reported cytoplasmic and membranous tissue pattern (HPA tissue IHC). Compare strong staining in placental trophoblastic cells and testicular Leydig cells with a negative control such as esophageal squamous epithelium (HPA tissue IHC).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
NECTIN3 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Cytoplasmic and membranous staining in most tissues (HPA tissue IHC) | |
| Staining pattern | Most tissues show cytoplasmic and membranous staining (HPA tissue IHC) | |
| Antigen retrieval | EDTA pH 8.0 HIER, heat-mediated (datasheet A09633-3) | |
| Positive control | Placenta+4 more · see all | |
| Negative control | Esophagus+2 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across sections. (standard IHC practice; not target-specific) | |
| Caveat | Tissue staining awaits external verification (HPA tissue IHC) | |
| Regulation | Regulation is not specified (UniProt) | |
| Isoform / epitope | 3 isoforms; map the epitope to the extracellular or cytoplasmic region (UniProt) |
Section 1
Recommended NECTIN3 IHC & IF Protocols
The catalog antibody’s IHC-P protocol is accompanied by two published chromogenic IHC protocols for NECTIN3 (PMC13562484; PMC9688614).
| Sample | Paraffin-embedded human rectal cancer tissue; fixative not specified (datasheet A09633-3) |
| Fixation | Image fixative and duration unreported (datasheet A09633-3); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: EDTA pH 8.0 (datasheet A09633-3); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet A09633-3) |
| Primary antibody | Rabbit anti-NECTIN3, 0.5-1μg/ml (datasheet A09633-3) |
| Primary incubation | Overnight at 4 °C (datasheet A09633-3) |
| Detection | Streptavidin-biotin complex (SABC), DAB chromogen (datasheet A09633-3) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | NECTIN3-positive staining in trophoblastic cells of placenta (HPA tissue IHC: High). HPA tissue profile: Cytoplasmic and membranous expression in most tisssues. No signal in the no-primary control. |
💡Decision noteStart with heat-mediated EDTA at pH 8.0 (datasheet A09633-3); if needed, compare citrate at pH 6.0 (PMC13562484).
Section 2
What Is the Expected NECTIN3 Staining Pattern?
NECTIN3 is a single-pass cell-surface protein associated with adherens junctions (UniProt Q9NQS3 topology and localisation). In paraffin-section IHC, expect membranous and some cytoplasmic staining (HPA: tissue IHC profile), including high staining in placental trophoblasts, testicular Leydig cells and thyroid glandular cells (HPA: tissue IHC). HPA rates the tissue profile Approved, with external verification pending (HPA: reliability).
| Cell borders stain, with some cytoplasmic signal, in trophoblasts, Leydig cells or thyroid glandular cells (HPA: tissue IHC). | This fits the reported high staining in those cells (HPA: tissue IHC) and NECTIN3's membrane and junction localisation (UniProt Q9NQS3). Cytoplasmic signal can be compatible with the HPA tissue profile; a perfectly sharp border is not required. |
| Strong staining is confined to nuclei, with little membrane or cytoplasmic staining. | An isolated nuclear pattern does not match the reported tissue pattern (HPA: cytoplasmic and membranous) or annotated localisation (UniProt Q9NQS3: membrane and junctions). Treat it as suspect and review morphology, controls and detection background before scoring it as NECTIN3. |
| Squamous epithelial cells in esophagus or vagina stain strongly, although the expected positive cells also stain. | HPA reports NECTIN3 as not detected in those squamous cells (HPA: tissue IHC). Review antibody specificity and, where applicable, endogenous chromogenic detection activity (general IHC practice). A positive control alone cannot establish that staining in an unexpected cell type is specific. |
| Color spreads across stroma, lumens or most cells without recognizable cell borders. | Diffuse staining is hard to reconcile with a cell-associated membrane and cytoplasmic pattern (HPA: tissue IHC; UniProt Q9NQS3 localisation). Consider nonspecific antibody binding or detection background (general IHC practice), and compare tissue architecture and control sections before interpreting weak cells. |
| Placental trophoblasts or testicular Leydig cells show no convincing staining. | Both are reported high in the HPA tissue survey (HPA: tissue IHC), so a blank result warrants a technical review. Confirm that the sampled cells are present, then check antibody dilution, retrieval, detection and control performance (general IHC practice). HPA's Approved profile still awaits external verification (HPA: reliability). |
💡Expected NECTIN3 appearanceCall positive when the expected cells show convincing membranous staining with possible cytoplasmic signal—especially high trophoblast, Leydig or thyroid glandular staining (HPA: tissue IHC); isolated nuclear or diffuse tissue-wide color is suspect (HPA: tissue IHC; UniProt Q9NQS3 localisation).
| Topology and epitope location (UniProt Q9NQS3 topology) | NECTIN3 has an extracellular region at residues 58–404, a transmembrane segment at 405–425 and a cytoplasmic tail at 426–549 (UniProt Q9NQS3). The supplied record does not locate the IHC antibody's epitope, so topology alone cannot predict which retrieval condition will work. |
| Processing and glycosylation (UniProt Q9NQS3) | A signal peptide spans residues 1–57; the annotated mature chain spans 58–549, with six listed glycosylation sites (UniProt Q9NQS3). These features describe the target but do not establish a fixation effect, a retrieval requirement or shedding in these sections. |
| Tissue choice and validation (HPA: tissue IHC; HPA: antibodies) | Placental trophoblasts, testicular Leydig cells and thyroid glandular cells are reported high; esophageal and vaginal squamous cells are reported not detected (HPA: tissue IHC). HPA lists two IHC antibodies as Approved, while the tissue profile remains pending external verification (HPA: antibodies and reliability). |
| IF/ICC Q&A: what localisation is reported? (HPA: subcellular) | HPA reports cell junction and cytosol localisation in ICC-IF images from U2OS, but labels both locations uncertain (HPA: subcellular). That observation offers a comparison for localisation; it does not establish an IF protocol or override the paraffin-section tissue IHC pattern. |
| Situation | Likely cause | Next action |
|---|---|---|
| Known-positive cells are blank (HPA: high trophoblasts or Leydig cells). | The section may lack the named cells, or an IHC workflow step may have failed (general IHC practice). The supplied sources give no NECTIN3-specific fixation sensitivity. | Verify cell identity on the section and compare a positive control processed alongside it. Check the recorded retrieval, primary-antibody dilution and detection steps (general IHC practice); avoid assigning the failure to fixation without evidence. |
| Only nuclei stain in otherwise intact tissue. | This compartment disagrees with HPA's membranous and cytoplasmic tissue profile and UniProt's membrane and junction annotations (HPA: tissue IHC; UniProt Q9NQS3). | Withhold a positive NECTIN3 call. Compare a no-primary control and a known-positive tissue, then review blocking and detection background (general IHC practice). |
| Esophageal or vaginal squamous cells show prominent color. | Those cells are reported not detected (HPA: tissue IHC); cross-reactivity or endogenous detection activity is possible (general IHC practice). | Compare a no-primary control and the expected positive cell types. If using an enzyme-based chromogen, check the appropriate endogenous-activity control (general IHC practice) before attributing color to NECTIN3. |
| The entire section has diffuse color that obscures cell borders. | Nonspecific binding or detection background can obscure the cell-associated pattern (general IHC practice; HPA: tissue IHC pattern). | Inspect the no-primary control and tissue morphology. Review blocking, washes, primary-antibody concentration and chromogen development under the assay's general IHC workflow. |
| A weak result appears in a tissue listed as low or medium. | HPA reports a range of levels across tissues and cell types (HPA: tissue IHC); weak staining there gives less assurance than a high positive reference. | Compare the named cell type with an HPA high reference and the assay controls before calling the weak signal absent or specific (HPA: tissue IHC; general IHC practice). |
| ICC-IF appears cytosolic or junctional, while IHC shows broader cytoplasmic staining. | HPA marks both ICC-IF locations uncertain, whereas its tissue IHC profile describes cytoplasmic and membranous expression (HPA: subcellular and tissue IHC). | Interpret each assay against its own controls and reported pattern. Do not use the uncertain ICC-IF localisation as a strict acceptance rule for paraffin-section IHC (HPA: subcellular and tissue IHC). |
Experiment evidence
IHC & IF images showing NECTIN3 staining
A09633-3 · IHCIHC analysis of Nectin 3/NECTIN3 using anti-Nectin 3/NECTIN3 antibody (A09633-3). Nectin 3/NECTIN3 was detected in paraffin-embedded section
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000177707-NECTIN3/tissue/cerebral+cortex#imid_3084816
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000177707-NECTIN3/tissue/colon#imid_3084750
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000177707-NECTIN3/tissue/liver#imid_3084751
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000177707-NECTIN3/tissue/kidney#imid_3084760
HPA · ICC-IF U2OSHuman Protein Atlas immunofluorescence, U2OS, antibody CAB009869; green = NECTIN3, blue = nucleus, red = microtubules.
HPA · ICC-IF U2OSHuman Protein Atlas immunofluorescence, U2OS, antibody CAB009869; green = NECTIN3, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for NECTIN3 IHC & IF
🧪Run placenta first: trophoblastic cells should stain (HPA: High in placental trophoblastic cells). Use esophagus as the negative tissue (HPA: Not detected in esophageal squamous epithelial cells); cells without specific staining on the placenta slide should show only counterstain and background chromogen (standard IHC practice).
Positive control tissue: Placenta (Trophoblastic cells, HPA High)
Negative control tissue: Esophagus (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show NECTIN3 in U2OS, with annotated localisation: Cell Junctions (uncertain), Cytosol (uncertain) (HPA subcellular).
Technical controls: Include a no-primary, secondary-only control, a matched rabbit IgG isotype control, and NECTIN3 knockout tissue if available (selected-SKU caption: rabbit primary antibody; standard IHC practice). For chromogenic staining, quench endogenous peroxidase and check for endogenous biotin background when using the caption’s streptavidin–biotin detection system (selected-SKU caption: SABC with DAB; standard IHC practice).
⚠️Feasibility: No target-specific fixation window or fixation effect is reported in the supplied evidence, and the selected A09633-3 paraffin-section caption does not state the fixative (selected-SKU caption: fixative not stated). That caption uses heat-mediated EDTA retrieval at pH 8.0; it supports trying that condition but does not establish that retrieval is required (selected-SKU caption: EDTA pH 8.0). Frozen sections are not established as easier by the supplied evidence, while IF/ICC localization in U2OS is marked uncertain (HPA subcellular: Cell Junctions and Cytosol, uncertain); on placenta, check biotin-related background if using SABC detection (selected-SKU caption: SABC; standard IHC practice).
HPA tissue IHC evidence for NECTIN3
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Approved — Pending external verification.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Placenta | Trophoblastic cells | High | Protein (IHC) | HPA → |
| Testis | Leydig cells | High | Protein (IHC) | HPA → |
| Thyroid gland | Glandular cells | High | Protein (IHC) | HPA → |
| Adipose tissue | Adipocytes | Medium | Protein (IHC) | HPA → |
| Adrenal gland | Glandular cells | Medium | Protein (IHC) | HPA → |
Section 3
Advanced NECTIN3 IHC Tips
Use compartment-aware controls and the documented paraffin-section method to troubleshoot NECTIN3 chromogenic IHC; assess IF separately.
Which retrieval condition should I try first when NECTIN3 staining is weak?
Start with heat-mediated antigen retrieval in EDTA at pH 8.0 for paraffin sections (datasheet A09633-3). The selected tissue-IHC example used that condition before staining, but its caption does not report a heating time or fixative (datasheet A09633-3). If signal remains weak, compare a second retrieval condition on matched sections while keeping antibody concentration and detection steps constant (standard IHC practice). Record tissue preservation alongside junctional and cytoplasmic signal, since excessive retrieval can impair morphology and make compartment assignment unreliable (standard IHC practice; UniProt Q9NQS3 localisation). Include a known positive section in each comparison to distinguish retrieval failure from low expression in the specimen (HPA: high in placental trophoblastic cells).
Could fixation explain weak or diffuse NECTIN3 staining?
Target-specific sensitivity to fixation is unknown from the supplied evidence, and the selected paraffin-section caption does not state its fixative (datasheet A09633-3). Document the specimen's fixative, fixation duration, processing history and section age before changing the staining method (standard IHC practice). Compare sections with similar handling using the documented EDTA pH 8.0 retrieval and 1 μg/mL primary antibody conditions (datasheet A09633-3). If morphology or signal differs, evaluate fixation as one possible contributor without assigning a NECTIN3-specific effect (standard IHC practice). A matched positive control helps separate a run-wide technical problem from specimen-dependent staining (standard IHC practice; HPA: high in placental trophoblastic cells).
Where should convincing NECTIN3 signal appear in chromogenic sections?
Assess cell borders and junctions first because NECTIN3 is a membrane protein associated with adherens junctions (UniProt Q9NQS3 localisation). Cytoplasmic staining can also occur in tissue IHC, although the HPA profile is approved pending external verification (HPA: cytoplasmic and membranous expression in most tissues; HPA: reliability description). Judge border signal against the tissue architecture and neighbouring cells rather than requiring every cell to show a continuous rim (standard IHC practice). In auditory epithelium specifically, the reported location is the apical side of supporting-cell lateral membranes (UniProt Q9NQS3 localisation). Record membrane and cytoplasmic staining separately so diffuse chromogen does not obscure the expected junctional pattern (UniProt Q9NQS3 localisation; standard IHC practice).
How should epitope uncertainty affect my interpretation of NECTIN3 staining?
NECTIN3 has 3 reported isoforms, so verify the catalog antibody's immunogen or mapped epitope before claiming that staining represents every isoform (UniProt Q9NQS3 isoforms; standard IHC practice). Its extracellular region spans residues 58–404, its transmembrane segment 405–425, and its cytoplasmic region 426–549 (UniProt Q9NQS3 topology). The extracellular region includes 6 annotated glycosylation sites, making epitope location relevant when investigating variable staining (UniProt Q9NQS3 glycosylation; standard IHC practice). If the epitope is undisclosed, report the result as antibody-detected NECTIN3 staining rather than isoform-specific expression (standard IHC practice). Use an independent antibody with a documented, distinct epitope when isoform or domain assignment is central to the conclusion (standard IHC practice).
How can I check a NECTIN3 IHC pattern by multiplex IF?
Treat multiplex IF as a separate assay and pair NECTIN3 with a validated marker for the expected cell type in the chosen specimen (standard IF practice). For example, a marker identifying trophoblastic cells could help assess placental signal, where HPA reports high NECTIN3 staining in that cell population (HPA: high in placental trophoblastic cells). Choose fluorophores after inspecting unstained tissue autofluorescence, and reserve a spectrally distinct channel for each marker (standard IF practice). Match permeabilisation to the antibody's epitope: an accessible extracellular epitope may need less permeabilisation than a cytoplasmic epitope (UniProt Q9NQS3 topology; standard IF practice). Include single-label and secondary-only controls before interpreting apparent junctional overlap (standard IF practice; UniProt Q9NQS3 localisation).
How do I troubleshoot widespread brown staining without losing junctional signal?
First compare a no-primary control with the stained section to identify signal arising from the detection system or tissue rather than primary-antibody binding (standard IHC practice). Check endogenous peroxidase blocking and inspect pigment or precipitate before treating diffuse brown material as NECTIN3 (standard IHC practice). The selected method used 10% goat serum blocking, 1 μg/mL primary antibody overnight at 4°C, and biotin-based DAB detection (datasheet A09633-3). If background persists, assess biotin-related signal with an appropriate detection control, then adjust blocking, washes or primary concentration on matched sections (standard IHC practice). Preserve enough signal to judge cell borders and cytoplasm separately (UniProt Q9NQS3 localisation; HPA: cytoplasmic and membranous expression).
What should I score when comparing NECTIN3 across sections? ⚠ ANSWER MARKED FOR VERIFICATION
Define the cell population and compartment before scoring, then report membrane and cytoplasmic staining separately (standard IHC practice; HPA: cytoplasmic and membranous expression). For intensity-based scoring, an H-score combines the percentage of cells at each intensity with its intensity grade; report the scoring scale used (standard IHC practice). For sparse positive cells, report positive cells per mm² of viable tissue or the percentage positive within the defined cell population (standard IHC practice). Normalise comparisons to eligible cells or viable tissue area, using comparable section quality and detection settings (standard IHC practice). Keep the same threshold and sampling plan across specimens, with the scorer blinded where feasible (standard IHC practice).
What distinguishes credible NECTIN3 staining from an artefact?
Credible staining should align with a plausible cell population and show interpretable membrane, junctional or cytoplasmic localisation (UniProt Q9NQS3 localisation; HPA: cytoplasmic and membranous expression). Placental trophoblastic cells and testicular Leydig cells offer reported high-expression comparisons, while esophageal squamous epithelial cells are reported as not detected (HPA: tissue-IHC profile). Treat isolated nuclear staining cautiously because the supplied localisation records place NECTIN3 at membranes, junctions and in cytoplasm or cytosol (UniProt Q9NQS3 localisation; HPA: subcellular summary). Check section edges, necrotic areas and no-primary controls for staining caused by tissue damage, uneven processing or endogenous enzyme activity (standard IHC practice). Resolve discordant patterns with matched controls and, when needed, a separately validated antibody (standard IHC practice).
Boster reagents
Best NECTIN3 / Nectin-3 IHC Antibodies
The catalog includes one human-reactive NECTIN3 antibody with chromogenic IHC data from a paraffin-embedded rectal cancer section (catalog: reactivity and applications; A09633-3 image caption). No IF data are supplied (catalog).
Real IHC data
Anti-Nectin 3/NECTIN3 Antibody ®
Cat # A09633-3
A09633-3 is listed for human IHC, with an image showing staining of a paraffin-embedded human rectal cancer section (catalog: applications and reactivity; A09633-3 image caption). Its catalog entry supplies no IF image or IF dilution (catalog).
Which to pick: For tissue IHC, choose A09633-3: its rabbit antibody is listed for human IHC at 0.5–1 μg/ml, and its chromogenic example uses a paraffin-embedded section with EDTA retrieval at pH 8.0 (catalog: host, applications, reactivity and IHC dilution; A09633-3 image caption). The caption does not report the fixative (A09633-3 image caption). There is no supported IF/ICC or cross-species pick in this payload: A09633-3 has no listed IF/ICC application or IF data, is listed for human reactivity only, and has no reported clone designation (catalog: applications, IF fields, reactivity and clone).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry Q9NQS3 (NECT3_HUMAN, Nectin-3).
- Human Protein Atlas. NECTIN3 tissue IHC expression (reliability: Approved).
- Human Protein Atlas. NECTIN3 subcellular location (ICC-IF): Localized to the cell junctions and cytosol..
- Human Protein Atlas. NECTIN3 antibody validation summary (2 antibodies).
- Tumor lymph node metastasis chip reveals that the NECTIN3-TIGIT axis promotes melanoma metastasis by enhancing treg cell function and inducing CD8(+) T cell exhaustion. Cellular oncology (Dordrecht, Netherlands) 2026 — PMC13562484.
- CD155 Cooperates with PD-1/PD-L1 to Promote Proliferation of Esophageal Squamous Cancer Cells via PI3K/Akt and MAPK Signaling Pathways. Cancers 2022 — PMC9688614.
- Single-cell transcriptomics reveals immune suppression and cell states predictive of patient outcomes in rhabdomyosarcoma. Nature communications 2023 — PMC10224926.
- Interactions between LAMP3+ dendritic cells and T-cell subpopulations promote immune evasion in papillary thyroid carcinoma. Journal for immunotherapy of cancer 2024 — PMC11141193.
- PubMed PMID:11024295 — UniProt-cited evidence.
- PubMed PMID:14702039 — UniProt-cited evidence.
- PubMed PMID:16641997 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for NECTIN3 (Nectin-3). Expected localisation Cytoplasmic and membranous staining in most tissues (HPA tissue IHC). Antigen retrieval: EDTA pH 8.0 HIER, heat-mediated (datasheet A09633-3). Validated IHC antibody: A09633-3 at 0.5-1μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Placenta (Trophoblastic cells); negative Esophagus. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human rectal cancer tissue; fixative not specified (datasheet A09633-3); 2. Fixation: Image fixative and duration unreported (datasheet A09633-3); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: EDTA pH 8.0 (datasheet A09633-3); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet A09633-3); 8. Primary antibody: Rabbit anti-NECTIN3, 0.5-1μg/ml (datasheet A09633-3); 9. Primary incubation: Overnight at 4 °C (datasheet A09633-3). Watch for: Fixation: Keep fixation consistent across sections. (standard IHC practice; not target-specific); Caveat: Tissue staining awaits external verification (HPA tissue IHC); Isoform / epitope: 3 isoforms; map the epitope to the extracellular or cytoplasmic region (UniProt); Regulation: Regulation is not specified (UniProt). Evidence: UniProt Q9NQS3, HPA tissue IHC · Approved, HPA ICC-IF · cell junctions and cytosol., Datasheet A09633-3, PMC13562484, PMC9688614. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/NECTIN3/immunohistochemistry-ihc-guide.